Is there a doseresponse relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study

Human Reproduction

Volumn 27, Issue 10, 2012, Pages 3057-3066

  Fulghesu, A M ^a   Romualdi, D ^b   Di Florio, C ^b   Sanna, S ^a   Tagliaferri, V ^b   Gambineri, A ^c   Tomassoni, F ^c   Minerba, L ^a   Pasquali, R ^c   Lanzone, A ^b,d  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

dose; insulin; metformin; PCOS

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYPROGESTERONE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; METFORMIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT;

ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN RELEASE; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MULTICENTER STUDY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PELVIC EXAMINATION; PROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY HOSPITAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; GLUCOSE TOLERANCE TEST;

ADULT; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; MENSTRUAL CYCLE; METFORMIN; POLYCYSTIC OVARY SYNDROME; TREATMENT OUTCOME;

EID: 84866355741     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/des262     Document Type: Article

References (39)

1. Apridonidze T, Essah PA, luorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929-1935.
2. Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001;76:517-524.
3. Bosi E. Metformin\the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes Obes Metab 2009;11 (Suppl. 2):3-8.
4. Bruno RV, de Avila MA, Neves FB, Nardi AE, Crespo CM, Sobrinho AT. Comparison of two doses of metformin (2.5 and l.5g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference, Fertil Steril 2007;88:510-512. Epub April 11.
5. Ciampelli M, Lanzone A. Insulin and polycystic ovary syndrome: a new look at an old subject. Gynecol Endocrinol 1998; 12:277-292.
6. Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Caruso A, Mancuso S, Lanzone A. Heterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 1997; 12:1897-1901.
7. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:942-947.
8. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995;49:721-749.
9. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352:1223-1236.
10. Fulghesu AM, Ciampelli M, Belosi C, Apa R, Pavone V, Lanzone A. A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertil Steril 2001;76:326-331.
11. Gambineri A, Tomassoni F, Gasparini DL, Di Rocco A, Mantovani V, Pagotto U, Altieri P, Sanna S, Fulghesu AM, Pasquali R. Organic cation transporter I polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2010;95:E204-E208.
12. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103:491-497.
13. Goodarzi MO, Bryer-Ash M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab 2005;7:654-665.
14. Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. j Clin Endocrinol Metab 2005;90:4593-4598. Epub 10 May.
15. Lee MG, Choi YH, Lee I. Effects of diabetes mellitus induced by alloxan on the pharmacokinetics of metformin in rats: restoration of pharmacokinetic parameters to the control state by insulin treatment. J Pharm Pharm Sci 2008; 11:88-103.
16. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA et al. Cooperative Multicenter Reproductive Medicine Network Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Englj Med 2007;356:551-566.
17. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA et al. Reproductive Medicine Network. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STKI I gene.J Clin Endocrinol Metab 2008;93:792-800.
18. Maciel GA, Soares Junior JM, Alves da Motta EL, Abi Haidar M, de Lima GR, Baracat EC. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004;8l:355-360.
19. Mansfield R, Galea R, Brincat M, Hole D, Mason H. Metformin has direct effects on human steroidogenesis. Fertil Steril 2003;79:956-962.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
21. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, antinsulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-termclinical evaluation. J Clin Endocrinol Metab 2000; 85:139-146.
22. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28:1039-1056.
23. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450cl7-activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335:617-623.
24. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450cl7 activity and serum androgens. J Clin Endocrinol Metab 1997; 82:4075-4079.
25. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Englj Med 1998;338:1876-1880.
26. New Ml, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, Dupont B, Stoner E, Levy DJ, Pang S et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 1983;57:320-326.
27. Onalan G, Goktolga U, Ceyhan T, Bagis T, Onalan R, Pabuccu R. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic. Eur J Obstet Gynecol Reprod Biol 2005; 123:204-21 I.
28. Palomba S, Falbo A, Zullo F, Orio F. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. J Endocr Rev 2009;30:1-50. Epub 4 Dec 2008 (Review).
29. Palomba S, Falbo A, Russo T, Orio F, Tolino A, Zullo F. Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. Hum Reprod 2010;25:IOO5-IO13.
30. Pasquali R, Stener-Victorin E, Yildiz BO, Duleba AJ, Hoeger K, Mason H, Homburg R, Hickey T, Franks S, Tapanainen JS et al. PCOS forum: research in polycystic ovary syndrome today and tomorrow. Clin Endocrinol 2011;74:424-433.
31. Peterkin BB. Dietary guidelines for Americans, 1990 edition. J Am Diet Assoc 1990;90:1725-1727.
32. Romualdi D, Costantini B, Selvaggi L, Giuliani M, Cristello F, Macrì F, Bompiani A, Lanzone A, Guido M. Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective. Hum Reprod 2008;23:2127-2133. Epub 20 June 2008.
33. Romualdi D, Giuliani M, Cristello F, Fulghesu AM, Selvaggi L, Lanzone A, Guido M. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertil Steril 2010;93:2303-2310.
34. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 2003; 14:365-370.
35. Song I, Shin H, Shim E, Jung I, Kim W, Shon J, Shin J. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 2008;84:559-562.
36. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012;5:CD003053.
37. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC 2010;8:41.
38. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647-654.
39. Weerakiet S, Sophonsritsuk A, Lertvikool S, Satirapot C, Leelaphiwat S, Jultanmas RJ. Randomized controlled trial of different doses of metformin for ovulation induction in infertile women with polycystic ovary syndrome. Obstet Gynaecol Res 2011;37:1229-1237.